Xiongwei Li

Scientist at Psioxus Therapeutics

Xiongwei Li's Professional Contact Details

Email (Verified)

****

Get Email Address

+44 1235 835328

Location

London, England, United Kingdom

Company

Psioxus Therapeutics

Person Seniority

entry

Xiongwei Li's Current Company Details

Psioxus Therapeutics

England, United Kingdom • 46 Employees

biotechnology

PsiOxus Therapeutics aims to be the world's leading immuno-oncolytic virus company, delivering medicines of value to patients with cancer. Our work is product and platform based with a focus on discovering and developing innovative immunotherapies for the treatment of solid tumors. Our products utilize enadenotucirev, our proprietary first generation oncolytic virus and our proprietary platform technology for next generation oncolytic viruses, Tumor-Specific Immuno-Gene Therapy (T-SIGn). The T-SIGn therapy platform is based on the company's oncolytic virus, enadenotucirev, which has properties that allow it to be delivered systemically via intravenous administration and to replicate only in tumor cells. The anti-cancer capability can be further enhanced through "arming" â€“ a process that involves the addition of new genes into the virus. The armed T-SIGn platform makes possible creation of a broad range of systemically delivered oncolytic immune therapeutics including oncolytic viruses that express one or more antibodies, cytokines, immunomodulatory proteins, or nucleotide (RNA) based payloads. The T-SIGn platform is in preclinical stage, while phase I/II clinical trials are ongoing with enadenotucirev in different tumor types and with different combinations including checkpoint inhibitors and conventional chemotherapeutics. Find our more about us at www.psioxus.com

Founded Year

2010

Organization Website

psioxus.com

Organization Languages

English

Organization Revenue

9600

Current Technologies

outlook

recaptcha

google maps non paid users